Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer. NPJ vaccines Valanparambil, R. M., Lai, L., Johns, M. A., Davis-Gardner, M., Linderman, S. L., McPherson, T. O., Chang, A., Akhtar, A., Gamarra, E. L., Matia, H., McCook-Veal, A. A., Switchenko, J., Nasti, T. H., Green, F., Saini, M., Wieland, A., Pinsky, B. A., Solis, D., Dhodapkar, M. V., Carlisle, J., Ramalingam, S., Ahmed, R., Suthar, M. S. 2023; 8 (1): 179

Abstract

This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4-6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.

View details for DOI 10.1038/s41541-023-00779-8

View details for PubMedID 37990024

View details for PubMedCentralID PMC10663480